文献速递系统性红斑狼疮

贝利尤单抗与标准治疗对SLE器官损伤进展的比较:倾向评分匹配分析

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
PubMed 文献 · Ann Rheum Dis · 2019-01-04

本研究比较BLISS长期扩展研究中接受贝利尤单抗的SLE患者与Toronto狼疮队列中倾向评分匹配的标准治疗患者的器官损伤进展。5年时贝利尤单抗组SDI评分变化显著低于标准治疗组(-0.434;95%CI -0.667至-0.201;p<0.001),且进展至更高SDI的风险降低61%(HR 0.391;95%CI 0.253至0.605;p<0.001)。

要点

  • 贝利尤单抗组5年SDI评分变化显著低于标准治疗组。
  • 贝利尤单抗组任意一年进展至更高SDI的风险降低61%。
  • 标准治疗组SDI增加≥2的比例高于贝利尤单抗组。

核心结论

  • 倾向评分匹配后,接受贝利尤单抗的SLE患者器官损伤进展显著少于标准治疗患者。

研究设计与样本

  • 研究206347为事后倾向评分匹配比较分析,贝利尤单抗组来自BLISS长期扩展研究,标准治疗组来自Toronto狼疮队列。
  • 系统文献回顾确定17项已知器官损伤预测因子以计算每例患者的倾向评分,按1:1匹配(卡钳值)。
  • 5年分析纳入567例(BLISS LTE n=195;TLC n=372),各队列99例1:1匹配。
  • 至器官损伤进展时间分析(随访≥1年)纳入965例(BLISS LTE n=259;TLC n=706),各队列179例匹配。

主要发现

  • 5年时贝利尤单抗组SDI评分变化显著低于标准治疗组(-0.434;95%CI -0.667至-0.201;p<0.001)。
  • 贝利尤单抗组任意一年进展至更高SDI的风险较标准治疗组降低61%(HR 0.391;95%CI 0.253至0.605;p<0.001)。
  • SDI评分增加中,增加≥2的比例在标准治疗组高于贝利尤单抗组。

关键数值与推荐

  • 主要终点为基线至5年SDI评分变化的差异。
  • 器官损伤进展定义为SDI评分进展至更高水平。

临床怎么用

  • 对于SLE患者,贝利尤单抗治疗可能与5年器官损伤进展较少相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study (206347) compared organ damage progression in patients with systemic lupus erythematosus (SLE) who received belimumab in the BLISS long-term extension (LTE) study with propensity score (PS)-matched patients treated with standard of care (SoC) from the Toronto Lupus Cohort (TLC). METHODS: A systematic literature review identified 17 known predictors of organ damage to calculate a PS for each patient. Patients from the BLISS LTE and the TLC were PS matched posthoc 1:1 based on their PS (±calliper). The primary endpoint was difference in change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score from baseline to 5 years. RESULTS: For the 5- year analysis, of 567 (BLISS LTE n=195; TLC n=372) patients, 99 from each cohort were 1:1 PS matched. Change in SDI score at Year 5 was significantly lower for patients treated with belimumab compared with SoC (-0.434; 95% CI -0.667 to -0.201; p<0.001). For the time to organ damage progression analysis (≥1 year follow-up), the sample included 965 (BLISS LTE n=259; TLC n=706) patients, of whom 179 from each cohort were PS-matched. Patients receiving belimumab were 61% less likely to progress to a higher SDI score over any given year compared with patients treated with SoC (HR 0.391; 95% CI 0.253 to 0.605; p<0.001). Among the SDI score increases, the proportion of increases ≥2 was greater in the SoC group compared with the belimumab group. CONCLUSIONS: PS-matched patients receiving belimumab had significantly less organ damage progression compared with patients receiving SoC.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019. PMID: 30610066. doi:10.1136/annrheumdis-2018-214043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。